Affinity is a clinical-stage biopharmaceutical company focusing on the development of global innovative anti-cancer drugs. It has the world’s first patented chemical coupling technology and an exclusive coupling Linker, which can upgrade traditional drug innovation to tumor microenvironment delivery and activation of new precision-guided drugs. Affinity recently announced that it has completed the A+ round of financing. This is the second round of financing that the company has won the favor of investment institutions after the company completed the A round of financing led by SDIC Ventures in September 2021. The total amount of the two rounds of financing amounted to several hundred million yuan. The A+ round of financing was invested by Hongfu Asset and Xingye Guoxin Asset Management, and Huaxing Capital acted as the exclusive financial advisor for this transaction.
This article is reproduced from: https://www.itjuzi.com/investevent/13325465
This site is for inclusion only, and the copyright belongs to the original author.